{"id":3013,"date":"2026-03-24T13:08:40","date_gmt":"2026-03-24T13:08:40","guid":{"rendered":"https:\/\/www.arcgroup.io\/oxford\/?p=3013"},"modified":"2026-03-24T15:07:38","modified_gmt":"2026-03-24T15:07:38","slug":"accession-therapeutics-awarded","status":"publish","type":"post","link":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/","title":{"rendered":"Accession Therapeutics awarded \u20ac7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapy"},"content":{"rendered":"\n<!-- Back button -->\n<div class=\"back-button-block__container\">\n\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/community\/\" class=\"back-button-block\">\n\t\t<svg class=\"back-button-block__arrow\" width=\"13\" height=\"13\">\n\t\t\t<use xlink:href=\"#small-arrow\"><\/use>\n\t\t<\/svg>\n\t\tBack to Community\t<\/a>\n<\/div>\n\n\n\n<section class=\"feature-banner\" id=\"block_f702958fc6b072cb742fe6dc2869e48f\"> \n    <div class=\"feature-banner__container\">\n            <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png 1200w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-300x169.png 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-1024x576.png 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-768x432.png 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-1000x563.png 1000w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-475x267.png 475w\" type=\"image\/png\" sizes=\"(max-width: 768px) 768px, (max-width: 1024px) 1024px, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png\" \/>\n            <\/picture>\n\n    <\/div>\n<\/section>\n\n\n<h2 class=\"wp-block-post-title\">Accession Therapeutics awarded \u20ac7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapy<\/h2>\n\n\n    <ul class=\"ed-post-categories\">\n                    <li class=\"arc-orange\">\n                <a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/category\/news\/\">News<\/a>\n            <\/li>\n            <\/ul>\n\n\n\n<p>ARC Oxford based, <a href=\"https:\/\/www.accessiontherapeutics.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Accession Therapeutics Limited<\/a>, a clinical-stage biopharmaceutical company developing next generation cancer immunotherapies, has been awarded \u20ac7.5 million (~\u00a36.5 million) in grant funding from Horizon Europe, the European Commission&#8217;s key funding programme for research and innovation, to advance the clinical development of the Company&#8217;s lead drug candidate, TROCEPT-01 (ATTR-01).<\/p>\n\n\n\n<p>TROCEPT-01 is a first-in-class, tumour-activated viral immunotherapy currently being evaluated in a Phase 1 open label clinical trail (ATTEST) in patients with advanced carcinomas. The ATTEST study is being conducted at leading clinical sites across the UK and Spain. Subject to final negotiation, the Horizon Europe grant will fund an expansion study in selected tumour indications in up to 24 participants as part of the ATTEST clinical trial to further explore the safety and efficacy of TROCEPT-01.<\/p>\n\n\n\n<p>TROCEPT-01 is delivered systematically and designed to selectively generate a clinically validated checkpoint inhibitor (anti-PD-L1) within tumours. This approach, targeting \u03b1v\u03b26 integrin on epithelial tumours, optimises efficacy while minimising damage to health tissue. Preclinical studies have demonstrated strong anti-tumour activity across multiple solid tumour models, supporting its potential as a targeted therapy for aggressive cancers.<\/p>\n\n\n\n<p><strong>Bent Jakobsen, PhD FMedSci, Chief Executive Officer of Accession Therapeutics<\/strong>, said: &#8220;We are delighted to receive this grant from Horizon Europe in collaboration with our partners, which recognises the potential of TROCEPT-01 (ATTR-01) as an innovative immunotherapy with applications across multiple solid tumour types. Alongside our ongoing ATTEST study, we look forward to continuing to build a body of data for TROCEPT-01 to validate our tumour-targeted immunotherapy platform, support future clinical trials and programmes and ultimately improve patient outcomes.&#8221;<\/p>\n\n\n\n<p>Accession Therapeutics is part of a thriving, diverse ecosystem of more than 30 science and innovation organisations at ARC&#8217;s Oxford Campus, including <a href=\"https:\/\/www.omass.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">OMass Therapeutics<\/a>, <a href=\"https:\/\/www.fluorok.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">FluoRok<\/a>, <a href=\"https:\/\/www.seloxium.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Seloxium <\/a>and <a href=\"https:\/\/perspectum.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Perspectum<\/a>. ARC last month announced the launch of <a href=\"https:\/\/www.arcgroup.io\/oxford\/properties\/motherlabs\/\" target=\"_blank\" rel=\"noreferrer noopener\">Motherlabs Oxford<\/a>, a purpose-build life sciences accelerator further expanding its early-stage laboratory offering in response to sustained sector demand.<\/p>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n    <section class=\"news-archive \" id=\"block_161890c780b129c5e8fc7b19d2dfbed2\">\n                    <div class=\"ed-container news-archive__title ed-archive-header__title ed-archive-header__title--large\">\n                <div class=\"ed-row\">\n                    <div class=\"ed-col ed-col__half\">\n                        \n                            <h3>More News<\/h3>\n                                            <\/div>\n                    <div class=\"ed-col ed-col__half\">\n                                                    <a href=\"https:\/\/www.arcgroup.io\/oxford\/community\/\" target=\"\">\n                                View all news &rarr;\n                            <\/a>\n                                            <\/div>\n                <\/div>\n            <\/div>\n                <div class=\"ed-container\">\n            <div class=\"ed-row\">\n                \n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/12\/childbase-partnership-announces-nursery-opening-at-arc-oxford\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image.jpg 1110w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-300x201.jpg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-1024x685.jpg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-768x513.jpg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-1000x668.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/12\/childbase-partnership-announces-nursery-opening-at-arc-oxford\/\" target=\"_self\">\n\t\t\t\tChildbase Partnership announces new Garsington Road day nursery opening at ARC Oxford\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/10\/oxa-raises-103m\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b.jpg 2402w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-300x200.jpg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-1024x682.jpg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-768x512.jpg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-1000x666.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/10\/oxa-raises-103m\/\" target=\"_self\">\n\t\t\t\tOxa Raises $103m in Series D First Close to supercharge Industrial Mobility Automation\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/02\/04\/arc-launches-motherlabs\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/02\/Motherlab-Copy-01160-scaled.jpg 2560w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/02\/Motherlab-Copy-01160-300x158.jpg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/02\/Motherlab-Copy-01160-1024x540.jpg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/02\/Motherlab-Copy-01160-768x405.jpg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/02\/Motherlab-Copy-01160-1000x527.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/02\/Motherlab-Copy-01160-scaled.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/02\/04\/arc-launches-motherlabs\/\" target=\"_self\">\n\t\t\t\tARC launches Motherlabs Oxford to support city&#8217;s growing life sciences spin-out ecosystem\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n            <\/div>\n        <\/div>\n    <\/section>\n","protected":false},"excerpt":{"rendered":"<p>ARC Oxford based, Accession Therapeutics Limited, a clinical-stage biopharmaceutical company developing next generation cancer immunotherapies, has been awarded \u20ac7.5 million (~\u00a36.5 million) in grant funding from Horizon Europe, the European Commission&#8217;s key funding programme for research and innovation, to advance the clinical development of the Company&#8217;s lead drug candidate, TROCEPT-01 (ATTR-01). TROCEPT-01 is a first-in-class, [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":1727,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","inline_featured_image":false,"footnotes":""},"categories":[22],"tags":[6210],"class_list":["post-3013","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-life-science-and-health"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Accession Therapeutics awarded \u20ac7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapy - ARC Oxford<\/title>\n<meta name=\"description\" content=\"Accession Therapeutics has been awarded \u20ac7.5 million in grant funding to advance the clinical development of the Company\u2019s lead drug candidate.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Accession Therapeutics awarded \u20ac7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapy - ARC Oxford\" \/>\n<meta property=\"og:description\" content=\"Accession Therapeutics has been awarded \u20ac7.5 million in grant funding to advance the clinical development of the Company\u2019s lead drug candidate.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/\" \/>\n<meta property=\"og:site_name\" content=\"ARC Oxford\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-24T13:08:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-24T15:07:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"nataliegelder\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"nataliegelder\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/\"},\"author\":{\"name\":\"nataliegelder\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3f1cd3ed5ba88a032f304b0bce8d3ee3\"},\"headline\":\"Accession Therapeutics awarded \u20ac7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapy\",\"datePublished\":\"2026-03-24T13:08:40+00:00\",\"dateModified\":\"2026-03-24T15:07:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/\"},\"wordCount\":330,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png\",\"keywords\":[\"Life science and Health\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/\",\"name\":\"Accession Therapeutics awarded \u20ac7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapy - ARC Oxford\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png\",\"datePublished\":\"2026-03-24T13:08:40+00:00\",\"dateModified\":\"2026-03-24T15:07:38+00:00\",\"description\":\"Accession Therapeutics has been awarded \u20ac7.5 million in grant funding to advance the clinical development of the Company\u2019s lead drug candidate.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/#primaryimage\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png\",\"width\":1200,\"height\":675,\"caption\":\"ARC Oxford Member, Accession Therapeutics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.arcgroup.io\/oxford\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Accession Therapeutics awarded \u20ac7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#website\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/\",\"name\":\"ARC Oxford\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\"},\"alternateName\":\"ARC Oxford\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.arcgroup.io\/oxford\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\",\"name\":\"ARC Oxford\",\"alternateName\":\"ARC Oxford\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png\",\"width\":2084,\"height\":2084,\"caption\":\"ARC Oxford\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3f1cd3ed5ba88a032f304b0bce8d3ee3\",\"name\":\"nataliegelder\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3fb7b427d3598506c2b50eb193a7e9ae080d5643e4b602a6b3b58a96341add54?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3fb7b427d3598506c2b50eb193a7e9ae080d5643e4b602a6b3b58a96341add54?s=96&d=mm&r=g\",\"caption\":\"nataliegelder\"},\"url\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/author\/nataliegelder\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Accession Therapeutics awarded \u20ac7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapy - ARC Oxford","description":"Accession Therapeutics has been awarded \u20ac7.5 million in grant funding to advance the clinical development of the Company\u2019s lead drug candidate.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/","og_locale":"en_US","og_type":"article","og_title":"Accession Therapeutics awarded \u20ac7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapy - ARC Oxford","og_description":"Accession Therapeutics has been awarded \u20ac7.5 million in grant funding to advance the clinical development of the Company\u2019s lead drug candidate.","og_url":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/","og_site_name":"ARC Oxford","article_published_time":"2026-03-24T13:08:40+00:00","article_modified_time":"2026-03-24T15:07:38+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png","type":"image\/png"}],"author":"nataliegelder","twitter_card":"summary_large_image","twitter_misc":{"Written by":"nataliegelder","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/#article","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/"},"author":{"name":"nataliegelder","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3f1cd3ed5ba88a032f304b0bce8d3ee3"},"headline":"Accession Therapeutics awarded \u20ac7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapy","datePublished":"2026-03-24T13:08:40+00:00","dateModified":"2026-03-24T15:07:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/"},"wordCount":330,"commentCount":0,"publisher":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#organization"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png","keywords":["Life science and Health"],"articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/","url":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/","name":"Accession Therapeutics awarded \u20ac7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapy - ARC Oxford","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/#primaryimage"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png","datePublished":"2026-03-24T13:08:40+00:00","dateModified":"2026-03-24T15:07:38+00:00","description":"Accession Therapeutics has been awarded \u20ac7.5 million in grant funding to advance the clinical development of the Company\u2019s lead drug candidate.","breadcrumb":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/#primaryimage","url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png","contentUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png","width":1200,"height":675,"caption":"ARC Oxford Member, Accession Therapeutics"},{"@type":"BreadcrumbList","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.arcgroup.io\/oxford\/"},{"@type":"ListItem","position":2,"name":"Accession Therapeutics awarded \u20ac7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapy"}]},{"@type":"WebSite","@id":"https:\/\/www.arcgroup.io\/oxford\/#website","url":"https:\/\/www.arcgroup.io\/oxford\/","name":"ARC Oxford","description":"","publisher":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#organization"},"alternateName":"ARC Oxford","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.arcgroup.io\/oxford\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.arcgroup.io\/oxford\/#organization","name":"ARC Oxford","alternateName":"ARC Oxford","url":"https:\/\/www.arcgroup.io\/oxford\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/","url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png","contentUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png","width":2084,"height":2084,"caption":"ARC Oxford"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3f1cd3ed5ba88a032f304b0bce8d3ee3","name":"nataliegelder","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3fb7b427d3598506c2b50eb193a7e9ae080d5643e4b602a6b3b58a96341add54?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3fb7b427d3598506c2b50eb193a7e9ae080d5643e4b602a6b3b58a96341add54?s=96&d=mm&r=g","caption":"nataliegelder"},"url":"https:\/\/www.arcgroup.io\/oxford\/blog\/author\/nataliegelder\/"}]}},"_links":{"self":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/3013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/comments?post=3013"}],"version-history":[{"count":0,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/3013\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/media\/1727"}],"wp:attachment":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/media?parent=3013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/categories?post=3013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/tags?post=3013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}